Latest Qiagen Stories

GERMANTOWN, Maryland and HILDEN, Germany, June 7, 2013 /PRNewswire/ -- - Expansion to about 20 validated gene panels will offer customers new opportunities for targeted clinical sequencing in a growing range of indications in cancer and other diseases - Driving adoption through ease of use, quality of results and compatibility with existing NGS workflows as well as with QIAGEN NGS platform now in development -...

GERMANTOWN, Maryland, and HILDEN, Germany, June 6, 2013 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that a U.S. reference laboratory customer of its HPV-related products used for cervical cancer screening has made public on June 6 a new non-exclusive agreement to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN has been informed that its HPV-related products will...

HILDEN, Germany and MARSEILLE, France, May 31, 2013 /PRNewswire/ -- - FGFR-TACC fusion genes, the target of potential targeted therapies for glioblastoma and other cancers, rights acquired from Columbia University - Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced two agreements...

CHICAGO, May 1, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include LinkedIn Corporation (NYSE:LNKD), AOL Inc. (NYSE:AOL), Facebook Inc. (Nasdaq:FB), Paychex Inc. (Nasdaq:PAYX) and Qiagen (Nasdaq:QGEN). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get the most...

VENLO, The Netherlands, April 29, 2013 /PRNewswire/ -- - Achieves Q1 2013 targets: Net sales of $303.6 million grow 3% CER on expansion in all regions; adjusted diluted EPS at $0.23 per share; free cash flow of $30 million - Progress toward accelerating innovation and growth in 2013: - Molecular Diagnostics (+11% CER) and Applied Testing (+5% CER) deliver solid results, more than offset weak market...

Role will help further advance revolutionary blood-based technology IRVING, Texas, March 5, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, announced today that it has named Joachim Schorr, PhD, as its Chief Scientific Officer. He joins Caris in this role after working as a consultant with the company during the past year. In this expanded capacity, Dr. Schorr's extensive expertise in the molecular...

MARCO ISLAND, Florida, and HILDEN, Germany, February 20, 2013 /PRNewswire/ -- - Streamlined and automated NGS workflow will offer many features required to enable routine use in clinical applications - Building on strengths in Sample & Assay Technologies to create an integrated NGS ecosystem with sample processing, genomic testing and bioinformatics - New consumable products address critical workflow challenges, expanding...

FREMONT, Calif., Feb. 19, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCBB: WGBS) announced today a co-marketing agreement with QIAGEN KK - a subsidiary of QIAGEN N.V.- for the joint promotion of certain products in Japan in the areas of genomics platforms such as Next-Gen sequencing (NGS) and qPCR. With the joint offering, customers will be able to seamlessly plan and execute complex research projects involving molecular biomarker discovery with NGS, where WaferGen's...

GERMANTOWN, Maryland and HILDEN, Germany, February 13, 2013 /PRNewswire/ -- - Arrangement to facilitate future collaborations in personalized medicine - Provides framework to develop and commercialize QIAGEN companion diagnostics paired with Lilly medicines in an effort to improve outcomes for individual patients - Builds on the two companies' recent mutual successes QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today...

VENLO, The Netherlands, January 29, 2013 /PRNewswire/ -- - QIAGEN exceeds Q4 and full-year 2012 targets: - Full-year 2012: Net sales advance 10% CER (+7% reported) to $1.25 billion on growth in all customer classes and regions; adjusted diluted EPS at $1.08 per share - Q4 2012: Net sales rise 4% CER (+4% reported) to $346.5 million, year-ago results included major product tender; adjusted diluted EPS at $0.34 per share -...